We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.12B
1-Year Est. Return
144%
This Fund
S&P 500
This Quarter
Est. Return
+12.81%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
-$275M
(-11%)
Cap. Flow
-$405M
Cap. Flow
% of AUM
-18.73%
Top 10 Holdings %
Top 10 Hldgs %
51.11%
Holding
71
New
13
Increased
14
Reduced
14
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$43.1M |
| 2 |
Editas Medicine
EDIT
|
+$30.1M |
| 3 |
Axsome Therapeutics
AXSM
|
+$28.3M |
| 4 |
ANI Pharmaceuticals
ANIP
|
+$22.8M |
| 5 |
Travere Therapeutics
TVTX
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$158M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$69.5M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$66.3M |
| 4 |
Biogen
BIIB
|
+$55.6M |
| 5 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$45.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
ANI Pharmaceuticals
ANIP
$1.86B
| $27.7M | 1.28% |
+514,021
| New | +$22.8M |
|
|
27
Axsome Therapeutics
AXSM
$11.7B
| $27.6M | 1.28% |
+384,200
| New | +$28.3M |
|
|
PNT
28
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $25.2M | 1.17% |
2,781,565
+436,492
| +19% | +$3.85M |
|
29
Edgewise Therapeutics
EWTX
$4.28B
| $21.3M | 0.99% |
2,750,000
-318,259
| -10% | -$2.68M |
|
30
Zura Bio
ZURA
$504M
| $20.7M | 0.96% |
+2,523,000
| New | +$20.3M |
|
31
Pacific Biosciences
PACB
$435M
| $19.3M | 0.89% |
1,451,201
-2,053,189
| -59% | -$25M |
|
32
Acumen Pharmaceuticals
ABOS
$152M
| $18.8M | 0.87% |
3,916,361
-35,639
| -0.9% | -$171K |
|
|
RAPT
33
DELISTED
RAPT Therapeutics
RAPT
| $18.8M | 0.87% |
125,570
+54,166
| +76% | +$8.44M |
|
34
PUT
Prothena Corp
PRTA
$448M
| $17.1M | 0.79% |
+250,000
| New | +$16.1M |
|
|
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
| $16.7M | 0.77% |
1,773,409
-251,728
| -12% | -$2.38M |
|
|
ATXS
36
DELISTED
Astria Therapeutics
ATXS
| $14.1M | 0.65% |
1,697,415
-119,116
| -7% | -$1.37M |
|
37
Nuvation Bio
NUVB
$2.29B
| $13.9M | 0.64% |
7,720,688
| – | – |
|
|
MORF
38
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $12.4M | 0.58% |
+216,752
| New | +$11.3M |
|
|
SLN
39
Silence Therapeutics
SLN
$546M
| $10.7M | 0.5% |
1,951,580
| – | – |
|
|
ORTX
40
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $10.6M | 0.49% |
2,041,670
+875,000
| +75% | +$4.46M |
|
41
Nektar Therapeutics
NKTR
$2.39B
| $10.3M | 0.48% |
1,198,231
+1,082,014
| +931% | +$11.5M |
|
|
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
| $9.62M | 0.45% |
+1,099,192
| New | +$12.8M |
|
|
ETNB
43
DELISTED
89bio
ETNB
| $9.53M | 0.44% |
503,100
-1,296,900
| -72% | -$22.8M |
|
|
INZY
44
DELISTED
Inozyme Pharma
INZY
| $9.16M | 0.42% |
1,644,021
-1,605,979
| -49% | -$9.49M |
|
45
Zentalis Pharmaceuticals
ZNTL
$332M
| $8.47M | 0.39% |
+300,300
| New | +$7.2M |
|
46
Relmada Therapeutics
RLMD
$540M
| $6.98M | 0.32% |
2,837,818
| – | – |
|
47
GH Research
GHRS
$1.92B
| $5.93M | 0.27% |
499,400
| – | – |
|
|
CMPS
48
Compass Pathways
CMPS
$1.47B
| $5.62M | 0.26% |
+678,360
| New | +$5.76M |
|
49
MoonLake Immunotherapeutics
MLTX
$1.56B
| $5.53M | 0.26% |
+108,450
| New | +$2.92M |
|
50
Century Therapeutics
IPSC
$364M
| $3.23M | 0.15% |
1,022,892
| – | – |
|
Similar funds
AWA
ACM
CIS
AA
JWBC
EMPI
HPG
B
Deep Track Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Deep Track Capital held 71 positions worth $2.16B, down 11% from $2.43B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Deep Track Capital withdrew a net $405M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.
Against the trend, Deep Track Capital opened a new position in Guardant Health worth $53.7M.
- Deep Track Capital's largest Q2 2023 buy was Guardant Health: 1,500,000 shares worth $53.7M.
- Deep Track Capital added most to Travere Therapeutics in Q2 2023, an estimated $22.2M increase.
- Deep Track Capital's biggest Q2 2023 reduction was Immunovant, cutting an estimated $37.5M.
- Deep Track Capital fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $158M.
- Deep Track Capital's ten largest holdings make up 51% of its $2.16B portfolio in Q2 2023.
- Deep Track Capital opened 13 new positions and closed 16 in Q2 2023.
- Deep Track Capital's portfolio value fell 11% quarter-over-quarter to $2.16B.
Based on Deep Track Capital's 13F filing for Q2 2023, filed 14 Aug 2023.